Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$238K Buy
677
+31
+5% +$11.1K 0.09% 189
2025
Q4
$211K Buy
+646
New +$205K 0.07% 196
2025
Q2
Sell
-646
Closed -$201K 188
2025
Q1
$201K Buy
+646
New +$191K 0.1% 171
2024
Q4
Sell
-798
Closed -$268K 174
2024
Q3
$268K Buy
798
+152
+24% +$49.7K 0.1% 179
2024
Q2
$202K Buy
+646
New +$190K 0.1% 169
2023
Q4
Sell
-836
Closed -$225K 166
2023
Q3
$225K Buy
+836
New +$209K 0.14% 143
2022
Q1
Sell
-1,336
Closed -$300K 149
2021
Q4
$300K Buy
+1,336
New +$282K 0.13% 163

Other funds holding AMGN

Autumn Glory Partners's AMGN Position: Q1 2026 in Review

Autumn Glory Partners increased its Amgen (AMGN) stake by 4.8% in Q1 2026, buying an estimated $11.1K and bringing the position to 677 shares worth $238K. The position accounts for 0.09% of the portfolio, ranked #189.

Autumn Glory Partners first reported a position in AMGN in Q4 2021 and has held it in 7 quarters since. The position peaked at $300K in Q4 2021. 3,129 funds tracked by Wall St. Rank hold AMGN as of Q1 2026.

  • Autumn Glory Partners held 677 shares of Amgen worth $238K as of Q1 2026.
  • Autumn Glory Partners bought 31 Amgen shares in Q1 2026, an estimated $11.1K.
  • Amgen made up 0.09% of Autumn Glory Partners's portfolio in Q1 2026, its #189 holding.
  • Autumn Glory Partners first reported a position in Amgen in Q4 2021 and has held it in 7 quarters since.
  • Autumn Glory Partners's Amgen position peaked at $300K in Q4 2021.
  • 3,129 funds tracked by Wall St. Rank held Amgen as of Q1 2026.

Based on Autumn Glory Partners's 13F filing for Q1 2026, filed 4 May 2026.